Axis-Shield & Abbott Laboratories in drug test deal
This article was originally published in Clinica
Abbott Laboratories will market and distribute an athletes' drug test to be developed and manufactured by Anglo-Norwegian company Axis-Shield under an agreement reached between the two companies last month. The test will screen athletes for levels of testosterone, abnormally high levels of which can indicate that an athlete is taking banned performance enhancing drugs. It will be used on Abbott's AxSym automated immunoassay testing platform, which combines continuous and random access and STAT capabilities.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.